Biotage AB (Biotage AB) ROCE % : 6.13% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biotage AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biotage AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 6.13%.

Biotage AB ROCE % Historical Data

The historical data trend for Biotage AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB ROCE % Chart

Biotage AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

21.59

20.42

18.12

18.39

10.32

Biotage AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															11.00	6.55	5.97	14.08	6.13

Biotage AB ROCE % Calculation

Biotage AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	30.806	/	( ( (225.381 - 40.181)	+	(480.717 - 68.73) )	/ 2 )
	=	30.806	/	( (185.2	+	411.987)	/ 2 )
	=	30.806	/	298.5935
	=	10.32 %

Biotage AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	25.74	/	( ( (480.717 - 68.73)	+	(494.367 - 66.37) )	/ 2 )
	=	25.74	/	( ( 411.987	+	427.997 )	/ 2 )
	=	25.74	/	419.992
	=	6.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Biotage AB (OTCPK:BITGF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biotage AB ROCE % Related Terms

Thank you for viewing the detailed overview of Biotage AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotage AB (Biotage AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIOT:Sweden 0GRP:UK PQX1:Germany

Address

Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03

Website

https://www.biotage.com

Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.